| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S40265-017-0783-4 |
| P698 | PubMed publication ID | 28667587 |
| P50 | author | Lesley J Scott | Q62563724 |
| P2860 | cites work | Diagnosis and classification of diabetes mellitus | Q22255452 |
| Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion | Q26740171 | ||
| Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation | Q26752294 | ||
| Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness | Q26771823 | ||
| Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors | Q26778608 | ||
| Practical combination therapy based on pathophysiology of type 2 diabetes | Q28076530 | ||
| Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q28254549 | ||
| Insulin glargine: an updated review of its use in the management of diabetes mellitus | Q35194343 | ||
| Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). | Q36303786 | ||
| Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials | Q36303980 | ||
| Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). | Q37106467 | ||
| Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L) | Q37106537 | ||
| Lixisenatide: a review of its use in patients with type 2 diabetes mellitus | Q38126893 | ||
| Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis | Q38249061 | ||
| Weight management in type 2 diabetes: current and emerging approaches to treatment | Q38496197 | ||
| Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes | Q38560857 | ||
| Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira | Q38622754 | ||
| Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus | Q38715053 | ||
| Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial | Q40955003 | ||
| Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome | Q41078909 | ||
| Basal insulin and cardiovascular and other outcomes in dysglycemia | Q42507791 | ||
| Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan- | Q42703474 | ||
| Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia | Q43650443 | ||
| Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. | Q51278923 | ||
| Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. | Q51280414 | ||
| Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. | Q51284082 | ||
| P433 | issue | 12 | |
| P921 | main subject | insulin glargine | Q417317 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 1353-1362 | |
| P577 | publication date | 2017-06-30 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes | |
| P478 | volume | 77 |
Search more.